Breast cancer 1 (BRCA1)-associated breast cancers are mostly basal-like high-grade ductal carcinomas that frequently overexpress epidermal growth factor receptor (EGFR). Aberrant EGFR expression is correlated with disease progression, resistance to radiation and chemotherapy, and poor clinical prognosis. Although BRCA1 is involved in multiple cellular processes, its functional role in EGFR regulation remains enigmatic. Here, we report a previously unrecognized posttranscriptional mechanism by which BRCA1 regulates EGFR expression through the induction of miR-146a. We demonstrate that EGFR expression correlates negatively with BRCA1, whereas miR-146a levels increase with BRCA1. We show that BRCA1 binds to MIR146A promoter and activates transcription, which in turn attenuates EGFR expression. Knockdown of miR-146a in BRCA1-overexpressing cells negated this effect and suppressed its ability to inhibit proliferation and transformation. In archived triple-negative breast cancer samples, we show a strong positive correlation between BRCA1 and miR-146a expression. We also show that low expression of miR-146a strongly predicts positive lymph node status and is associated with distinctively poor overall survival of patients. Together, these observations provide an insight into a novel BRCA1 → miR-146a → EGFR paradigm by which BRCA1 carries out an aspect of tumor suppressor function that is potentially amenable to therapeutic intervention.
INTRODUCTION
Mutations in the tumor suppressor BRCA1 (breast cancer 1, early onset) predispose women to an 80% lifetime risk of breast cancer and a 40% lifetime risk of ovarian cancer. 1, 2 Breast cancer is a heterogeneous disease, and gene expression profiling has demonstrated five major subtypes, including the basal-like 3 subtype that is enriched for tumors with genetic and/or epigenetic inactivation of BRCA1. BRCA1-associated tumors commonly display a triple-negative (TN) phenotype lacking expression of estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). They are mostly basal-like high-grade ductal carcinomas, frequently overexpress epidermal growth factor receptor (EGFR/ErbB1/HER1) and basal cytokeratins (CK5, CK6, CK14 and CK17), and tend to be highly proliferative and invasive. 4 A number of studies have implicated the basal cell as the cell of origin of BRCA1-associated basal-like breast cancers (BLBCs), whereas others identify them as luminal progenitor cells that could be targets for oncogenic events. [5] [6] [7] About 30-40% of sporadic breast cancers either do not express or have significantly decreased levels of BRCA1 8, 9 and show a strong histological resemblance to BRCA1-associated hereditary tumors. 2, 10 EGFR is a member of the HER family of transmembrane receptor tyrosine kinases that is widely expressed in different human tissues. 11 Although EGFR is essential for important cellular processes including proliferation, differentiation and development, it can contribute to the development and growth of cancer when atypically expressed or activated. 12 EGFR overexpression occurs in a range of solid tumors and is associated with tumor progression and metastasis, resistance to radiation and chemotherapy, and poor prognosis. 13, 14 Low expression of EGFR is generally associated with good prognosis in cancers, and several studies have specifically demonstrated a negative correlation between EGFR status and relapse-free and overall survival from breast cancer. [14] [15] [16] A significant association between increased EGFR expression and BRCA1 mutation/deficiency has been reported in several independent studies, 17, 18 but whether there is a mechanistic basis for this consistent observation has thus far been undetermined.
BRCA1 is located on chromosome 17q21 and encodes a 1863amino-acid nuclear phosphoprotein with an N-terminal RING domain and C-terminal BRCT motifs. These highly conserved domains of BRCA1 are frequently affected by clinically important mutations resulting in genomic instability. BRCA1 exerts its tumor suppressor function primarily by interacting with multiple proteins through its RING domain and BRCT motifs to form large nuclear complexes that are critical for DNA repair and maintenance of genomic stability. 19, 20 Other functions of BRCA1 that contribute to its tumor suppressor activity include mammary epithelial differentiation, transcriptional activation and repression and chromatin remodeling. 5, [20] [21] [22] MicroRNAs (miRNAs) are a class of evolutionarily conserved small noncoding RNAs~21 nucleotides in length that regulate the expression of more than one-third of the genes in the human genome by inhibiting translation or by promoting mRNA degradation via sequence-specific interaction with the 3′UTR of the cognate mRNA targets. 23, 24 miRNAs function as oncogenes or tumor suppressors and show characteristic expression signatures in different cancers, predicting disease status and prognosis. They are implicated in stem and epithelial cell differentiation, epithelialto-mesenchymal transition and invasion and metastasis. 25 A potential role for miRNAs in the regulation of EGFR in breast and other cancers has recently gained acceptance. 26, 27 EGFR upregulation is suggested to occur via multiple transcriptional and posttranscriptional mechanisms including gene amplification, C-terminal truncation, transcriptional activation and posttranslational modifications. 28 Yet, a mechanism that connects the loss of BRCA1 to the overexpression and activation of EGFR that contributes to BLBC pathogenesis has not been identified. In this regard, a unique mechanism involving miRNAs was investigated to reveal this critical missing link and to uncover novel therapeutic options for this deadly disease.
RESULTS

BRCA1 deficiency results In upregulation of EGFR
To investigate the relationship between EGFR expression and BRCA1 status, western blots for BRCA1 and EGFR were performed on extracts of breast and ovarian cancer cell lines representing different molecular subtypes, namely MCF7 and T47D (Luminal type, ER + /PR + /HER2 − ), BT-474 and SKBR3 (HER2 enriched, ER − /PR − / HER2 + ), MDA-MB-231, MDA-MB-436, MDA-MB-468 and BT-20 (basal type, ER − /PR − /HER2 − ), MCF10DCIS.com and SUM-225 (ductal carcinoma in situ (DCIS) cell lines, basal-like DCIS model and HER2-overexpressing DCIS model, respectively) and SKOV3 (ovarian cancer cells, ER + /PR − /HER2 + ). Similarly, we tested for BRCA1 and EGFR expression in HCC1937, a basal breast cancer cell line that is homozygous for the BRCA1 5382insC mutation, HMLE, immortalized human mammary epithelial cells and MCF10A, immortalized non-transformed mammary epithelial cells. As shown in Figures 1a and c, high EGFR protein expression was associated with basal-type cell lines and low EGFR levels with luminal-type cell lines. HCC1937 cells that do not express functional BRCA1 display high EGFR protein expression ( Figure 1a ). HMLE and MCF10A cells on the other hand express considerable amounts of BRCA1 with minimal EGFR levels. An inverse correlation between BRCA1 and EGFR protein expression is observed in the cell lines tested. qRT-PCR of BRCA1 and EGFR (Figures 1b and d ) revealed a somewhat similar pattern in most of the cell lines, further suggesting a negative relationship between BRCA1 and EGFR expression.
Next, we analyzed HMLE cells infected with three different lentiviral clones of BRCA1 shRNA. Interestingly, depletion of BRCA1 resulted in a significant increase in EGFR protein expression, the increase reflecting the extent of BRCA1 knockdown (Supplementary Figure S1A ). Densitometry of the immunoblots showed that EGFR levels increased as much as 600% upon BRCA1 depletion (Supplementary Figure S1B ). qRT-PCR analysis revealed that BRCA1 knockdown elicited only marginal changes in EGFR mRNA expression ( Supplementary Figure S1C) , implicating a possible posttranscriptional mechanism for EGFR regulation.
Similar results were observed in HeLa cells, further substantiating our findings (Supplementary Figures S1D and E).
BRCA1 regulates EGFR activation
To investigate this further, we analyzed parental HCC1937 and HCC1937/WT BRCA1 (hereafter referred to as HCC1937B), a cell line in which BRCA1 has been restored by expression of full length BRCA1 cDNA. A significant decrease in total EGFR protein was observed when WT BRCA1 was re-expressed in the BRCA1defective HCC1937 (Figure 2a ; Figure 2c , lanes 9 and 10). In addition to overexpression of total EGFR, we also observed a noticeable increase in p-EGFR (Y-1068) in BRCA1-deficient cells. A moderate decrease in EGFR mRNA level was noticed in HCC1937B cells ( Figure 2b ). Subcellular fractionation of HCC1937 and HCC1937B cells showed accumulation of p-EGFR (Y-1068) in the cytoplasm of BRCA1 null cells (Figure 2c , lanes 1 and 2). We also observed a pronounced increase in total EGFR in the membrane and cytosol ( Figure 2c, lanes 1-4) , and a small amount in the nuclear fractions in BRCA1 null cells (Figure 2c , lanes 5 and 6). Together, the data confirm that augmented EGFR expression accompanying BRCA1 deficiency is also associated with activation of EGFR, as demonstrated by phosphorylation of a specific tyrosine residue within the cytoplasmic domain.
We have shown an inverse correlation between BRCA1 and EGFR protein expression in multiple cell lines. Our data demonstrate that EGFR protein overexpression in BRCA1 deficiency far exceeds the change in its mRNA levels. Therefore, we hypothesized that BRCA1 could regulate EGFR posttranscriptionally through a novel mechanism involving miRNAs. Using this rationale, we studied miRNAs with respect to BRCA1 and found that miR-146a has a critical role in this process.
BRCA1 enhances miR-146 expression
We performed miRNA profiling on HMLE and HCC1937, in which BRCA1 was depleted and overexpressed, respectively. Analysis of array data revealed that distinct miRNAs were differentially regulated by BRCA1, exhibiting very high similarity regarding BRCA1 gain/loss in the two isogenic cell lines tested. The complete results of miRNA array are shown in Figure 3 . From the several miRNAs that showed BRCA1-dependent regulation and that are also involved in EGFR signaling, we selected miR-146a based on its tumor suppressor function, its ability to target EGFR and its profound differential expression with respect to BRCA1 levels in both the cell lines. Further validation of our array data clearly illustrated significant regulation of the miR-146 family of miRNAs, with a profound increase in miR-146a in BRCA1-expressing cells ( Figure 4a ). Individual validation of miR-146a and miR-146b by qRT-PCR revealed that there was a 20-25-fold increase in both miR-146a and miR-146b in WT BRCA1-expressing HCC1937 (Figure 4b ). In HMLE cells on the other hand, miR-146a was found to be downregulated by~80% in BRCA1 deficiency, whereas the effect was less significant for miR-146b ( Figure 4c ).
To investigate if miR-146a expression could serve as an important prognostic biomarker in BRCA1-associated BLBC, we performed qRT-PCR analysis of 27 archived TN breast cancers. From Kaplan-Meier survival analysis, we observed that low expression of miR-146a was associated with distinctively poor overall survival of patients ( Figure 4d) . Fisher's test shows a trend with miR-146a expression and lymph node status, with the above median expression strongly predicting negative lymph node status ( Figure 4e ). miR-146a expression in the clinical samples was found to be closely correlated with BRCA1 expression levels (Figure 4f ). BRCA1 and miR-146a regulate EGFR expression BRCA1 binds to MIR146A promoter and activates its transcription In order to understand the role of BRCA1 in the regulation of miR-146a biogenesis, we analyzed the levels of primary transcript, precursor and mature miR-146a in HCC1937 and HCC1937B cells by qRT-PCR. Our results indicated that in WT BRCA1 cells, the expression levels of all the three forms of miR-146a increased by about 15-20-fold compared with mutant BRCA1 cells (Figure 5a ), suggesting a role of BRCA1 in miR-146a transcription and not biogenesis.
To investigate whether BRCA1 augments transcription of MIR-146A by binding to its putative promoters, we carried out a chromatin immunoprecipitation assay. Semi-quantitative PCR analysis of DNA, immunoprecipitated from HeLa and HMLE cells using the anti-BRCA1 C-terminal antibodies confirmed the recruitment of BRCA1 to MIR146A promoter ( Figure 5b ).
We performed luciferase reporter assays to confirm that MIR146A promoter is indeed activated by BRCA1. The promoter region for MIR146A is located between 17 060 and 17 550 bases upstream from the mir-146a coding sequence. 29 Luciferase activity was measured after 48 h in HMLE cells co-transfected with pGL3-miR-146a-luc construct (containing the promoter region of MIR146A) along with either control siRNA or siRNA to BRCA1. Results showed that BRCA1 knockdown attenuated MIR146A promoter activity by~45% compared with that of control ( Figure 5c ).
We further sought to identify the BRCA1-binding sites on the MIR146A promoter. We found 13 putative BRCA1-binding sites on the MIR146A promoter (JASPAR database; 30 Supplementary Figure  S2A ). Of the 13, 8 matched Chip-Seq data (GEO Accession: GSM935377), with 5 of them showing frequency-matrix match over 0.80. To validate the interactions in vitro, we mutated seven of the eight target sequences individually (Figure 6a ), transfected HMLE cells with luciferase constructs containing WT or MIR146A promoter mutants and measured the luciferase activity following BRCA1 knockdown. All the seven mutants showed significant decrease in promoter activity compared with WT, with mutants 3, 4 and 5 showing the most profound effect (Figure 6b ). Mutations to BRCA1-binding sites 3, 4 or 5 led to the loss of BRCA1 sensitivity on the promoter as measured by luciferase activity, suggesting the importance of these binding sites in promoter activation by BRCA1 (Figure 6b ).
To further identify the region of BRCA1 critical for binding to the MIR146A promoter, we infected HMLE cells with adenoviruses expressing HA-tagged WT and mutant BRCA1 31 ( Supplementary  Figures S2B,S2C) , then transfected the cells with WT MIR146A promoter luciferase construct and performed luciferase assay. Our results indicate that the N-terminal RING and the C-terminal BRCT domains of BRCA1 are important in binding to MIR146A promoter, as exogenous expression of protein lacking these domains did not have any significant effect on the MIR146A promoter luciferase activity compared with control ( Supplementary Figures S2D and  6C ). Overexpression of WT and the two other deletion mutants on the other hand showed significant increase in luciferase activity. Our data corroborates earlier published reports on the importance of the RING and BRCT domains of BRCA1 in protein/protein and protein/DNA interactions. 20 miR-146a regulates EGFR expression Both miR-146a and miR-146b have been shown to regulate EGFR in different cell types. 26, 32, 33 To establish that miR-146a directly regulates the expression of EGFR in mammary epithelial cells, we transfected HMLE cells with miR-146a LNA or mimics. qRT-PCR of miR-146a after 48 h shows significant knockdown and overexpression upon transfection with LNA and mimic, respectively (c) BRCA1 deficiency results in increased activation of EGFR: whole-cell lysate and different subcellular fractions of HCC1937 and HCC1937B, cytoplasm, membrane, nuclear and chromatin were subjected to electrophoresis and probed for BRCA1, p-EGFR and EGFR. SP1, GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and histone H3 were used as cell fractionation markers for nuclear, cytoplasmic and chromatin fractions, respectively.
BRCA1 and miR-146a regulate EGFR expression
Fiugres S3B and C. Immunoblots revealed a significant increase in p-EGFR (Y-1068) and EGFR in HMLE upon miR-146a knockdown ( Figure 7d ) and a dramatic decrease upon its overexpression (Supplementary Figure S3D ). Subcellular fractionation of LNA-transfected HMLE revealed accumulation of EGFR in the membrane fraction (Supplementary Figure S3E ) and also some expression in the nucleus similar to BRCA1-deficient cells. Similar results were observed in HeLa cells and MDA-MB-231 ( Supplementary Figures S3F, G, H) . These results collectively substantiate that miR-146a represses EGFR in mammary cells.
Analysis of miR-146a binding to the 3'UTR of EGFR In order to assess whether miR-146a directly targets the 3'UTR of EGFR, we co-transfected HMLE and HeLA cells with a pEZX EGFR 3'UTR-luciferase-reporter construct and miR-146a mimic. We observed that the luciferase activity in cells transfected with miR-146a mimic decreased by 60% in HMLE ( Figure 7e ) and 30% in HeLa (Supplementary Figure S4A ) cells compared with cells transfected with control mimic.
We further investigated miR-146a binding to its specific target sequences within the 3′UTR of EGFR. We identified 21 high-affinity (minimal free energy, MFE ⩽ − 20 kcal/mol) miR-146a targets in the 3'UTR of the EGFR mRNA, with the strongest target located 1064 bp into the 3'UTR (Supplementary Figure S4B) . To validate the miR-146a binding region on the 3′UTR of EGFR in vitro, we mutated three of the highest-affinity target sites within the 3′UTR (Figure 8a, Supplementary Figure S4B ). Co-transfection of miR-146a mimic with WT-EGFR 3′UTR luciferase construct resulted in significant inhibition of luciferase activity (Figure 8b ). Mutagenesis of the miR-146a-binding sites within the EGFR 3′UTR resulted in an increase in the luciferase activity and also completely abolished the ability of miR-146a to regulate EGFR 3′UTR luciferase expression. The result was more pronounced in mutant 2, located at 1064 bp, which was also the strongest hit in our in silico analysis (Supplementary Figure S4B) . Thus, we have demonstrated for the first time that EGFR is a direct target of miR-146a.
miR-146a is downstream of BRCA1 and mediates the regulation of EGFR by BRCA1
We hypothesized that miR-146a is a key mediator of the effect of BRCA1 on EGFR expression. In order to test if the knockdown of miR-146a can reverse the effect of BRCA1 on EGFR expression, we transfected HCC1937 and HCC1937B cells with LNA to miR-146a and evaluated the expression of miR-146a, BRCA1 and EGFR by qRT-PCR. There was a significant knockdown of miR-146a in both mutant and BRCA1-complemented HCC1937 cells upon LNA transfections (Figure 9a ). Western blot analysis revealed that BRCA1 reconstitution in HCC1937 considerably decreased EGFR protein expression, consistent with our prior observations. Most importantly, the knockdown of miR-146a in BRCA1-overexpressing HCC1937 cells was able to rescue EGFR protein expression ( Figure 9b ). Results demonstrate that BRCA1 regulation of EGFR expression is dependent on miR-146a. The fact that miR-146a knockdown could rescue EGFR expression, which is otherwise downregulated by BRCA1, suggests that miR-146a is critical to this function. There was no significant change in BRCA1 and EGFR mRNA levels upon LNA transfections (Figures 9c and d) . We observed a small increase in BRCA1 protein expression upon LNA transfection in the HCC1937B (Figure 9b ) cell line. Similar results were noticed in mutant and BRCA1-complemented HCC1937 transfected with mimics ( Supplementary Fig. S5A-D) . BRCA1 levels were found to decrease upon mimic transfection (Figure 10e ) suggesting a feedback regulation. A model illustrating the posttranscriptional regulation of EGFR by BRCA1 is depicted in Figure 9e .
BRCA1 and miR-146a deficiency leads to hyperproliferation of cells and enhanced clonogenic growth
Additional functional studies were carried out to support the novel molecular mechanism by which BRCA1 and miR-146a regulate the initiation and development of BLBC by targeting EGFR and its downstream signaling pathway. BRCA1 overexpression resulted in significant reduction in cell proliferation (HCC1937 vs HCC1937B; Figure 10a ), corroborating previous reports that BRCA1-deficient cells proliferate faster than their BRCA1-proficient counterparts. 20 miR-146a knockdown increased cell proliferation in both HCC1937 and HCC1937B cells. Most importantly, knockdown of miR-146a in HCC1937B cells significantly rescued cell growth by~40% compared with control ( Figure 10a ) at 48 h posttransfection. Cell cycle analysis showed a 20-30% increase in the percentage of cells in S phase in both HCC1937 and HCC1937B cells upon LNA miR-146a transfection ( Supplementary Figures S6A & B) . In clonogenic cell survival assay, knockdown of miR-146a significantly increased the number of surviving colonies by about twofold (Figure 10b ), whereas its overexpression showed the opposite effect ( Supplementary Figures S6C) . Western blots performed after BRCA1 and miR-146a overexpression and EGFR knockdown in HCC1937 show a strong decrease in EGFR, Raf-1 and Ras, and an increase in cleaved PARP and caspase-3 levels in HCC1937B compared with HCC1937 ( Figure 10c ), and in siEGFR transfected HCC1937 cells compared with control ( Figure 10d ). Similar results were also observed in miR-146a mimic-transfected cells compared with control, with the exception of caspase-3 that did not show much difference (Figure 10e ). BRCA1 and miR-146a deficiency lead to enhanced mammosphere formation It has been shown that signaling through EGFR is required for the mammosphere formation and that breast cancer stem cells are EGFR positive. 34 To understand the effect of miR-146a loss on anchorage-independent growth, we selected the in vitro The seven binding sites are indicated in blue and the mutations generated in these regions are shown in red. Their relative distance from the mature miR-146a is represented below in black. (b) Luciferase activity of WT and mutant miR-146a promoter in HMLE cells following BRCA1 silencing compared with scrambled control is shown. **Po0.001 (Student's t-test). (c) miR-146a luciferase activity in HMLE cells upon overexpression of WT BRCA1 and the different deletion mutants (WT: Full length, ΔΝːΔ1-302 aa, Δ1:Δ305-770aa, Δ2: Δ775-1292aa, ΔC: Δ1527-1863aa) (see Supplementary Figure S2 ) compared with control virus are shown. Luciferase activity obtained with the WT and the different deletion mutants was normalized to the protein expression from western blots. **Po0.001 (Student's t-test). See also Supplementary Figure S2 .
BRCA1 and miR-146a regulate EGFR expression mammosphere culture system that enriches for putative stem/ progenitor cells and that is capable of differentiation. 35 Knockdown of miR-146a expanded both the primary and secondary mammospheres count by about twofold, whereas overexpression diminished the count by 30-40% compared with control ( Figures  10f and g) . These experiments were also repeated using HCC1937 and HCC1937B cells. BRCA1 overexpression in the HCC1937 basal cell line profoundly decreased the mammosphere population, whereas knockdown of miR-146a in BRCA1-expressing cells offset its effect, resulting in a 10-fold increase of mammospheres (Figure 10h ).
DISCUSSION
Loss of functional BRCA1 and concomitant EGFR overexpression has been consistently observed in BLBCs by multiple groups. 17, 18 Up to this point, this observation has always been a phenomenon indirectly related at best, without a mechanistic explanation. In the current study, we investigated the relationship between EGFR expression and BRCA1 status and provided evidence that BRCA1 regulates EGFR expression posttranscriptionally. We demonstrate that BRCA1 binds to and transactivates the MIR146A promoter. We also show that the regulation of EGFR by BRCA1 is attenuated in the absence of miR-146a. Taken collectively, our results convincingly support a role for BRCA1 in the regulation of EGFR expression via miR-146a. This essential link in the mechanism, which connects the loss of functional BRCA1 to the overexpression of EGFR, may provide novel options for preventive therapies in the future and may have functional consequences for the use of EGFR inhibitors in BRCA1-associated breast cancers.
Among TN breast cancers, the poor prognosis is strongly influenced by the presence of EGFR or basal cytokeratins. 13, 14 Burga et al. 36 have demonstrated that the inhibition of BRCA1 leads to the upregulation of EGFR and increases clonal growth in human mammary epithelial cells. Here, we show a direct negative correlation between BRCA1 and EGFR protein expression in breast cancer cell lines representing the different intrinsic tumor subtypes. In addition to the different cell lines where BRCA1 could either be mutated or epigenetically inactivated, we also show that BRCA1 knockdown in HMLE results in the upregulation of EGFR, whereas BRCA1 reconstitution in the BRCA1-mutant HCC1937 results in significant reduction in the expression of EGFR. Our results therefore demonstrate that, in addition to BRCA1 mutational status, the overall expression levels of functional BRCA1 is very important in the regulation of EGFR.
Interestingly, the regulation of EGFR expression by BRCA1 appears to occur without major changes in its mRNA, suggesting a predominantly posttranscriptional mechanism, and our study reveals that this regulation occurs via miR-146a. miR-146a is a member of the miR-146 miRNA family consisting of two evolutionarily conserved miRNA genes, MIR146A and MIR146B that differ in their mature sequence only by 2 bases at the 3′ end. miR-146a was first discovered as an integral component of a negative feedback mechanism in the innate immune system. 29 There was a 20-fold decrease or increase of miR-146a expression upon BRCA1 depletion or overexpression in HMLE and HCC1937, respectively. Our results are consistent with the study by Tanic et al. 37 that reported upregulation of miR-146a upon BRCA1 reconstitution in HCC1937. Garcia et al. 38 have shown that miR-146a and miR-146b downregulate BRCA1 in TN breast cancers. In our experiments with LNA and mimic miR-146a transfections, we also observed an increase and decrease, respectively of BRCA1 protein expression. The mechanism underlying this feedback regulation of BRCA1 and miR-146a that maintains their levels in a perfect homeostasis needs further investigation. Several epidemiological studies have evaluated the association between miR-146a polymorphisms, their capacity to bind to the 3′UTR of BRCA1, and breast cancer risk. 39 Additional studies are required to assess the importance of this polymorphism in the potential feedback loop.
In a recent study, it has been reported that BRCA1 increases the expression of precursor and mature forms of cancer-associated specific miRNAs by accelerating the microprocessor DROSHAmediated processing of their primary transcript in vitro and in vivo. 40 Our qRT-PCR analysis of the various stages of miR-146a biogenesis showed a uniform increase in expression levels of primary transcript, precursor and mature miR-146a with increase in BRCA1 suggesting, that BRCA1 regulation of miR-146a is transcriptional and not through miRNA biogenesis.
Chromatin immunoprecipitation analysis and promoter luciferase assays provide additional evidence that BRCA1 binds to the promoter of MIR146A and transcriptionally activates it. The role of BRCA1 as a transcriptional coregulator/corepressor is well known. 21, 22, 41 Chang et al. 42 have shown that BRCA1 plays a role in the epigenetic regulation of the oncogenic miR-155 via its interaction with the HDAC complex. Their study shows that BRCA1 associates with the miR-155 promoter and suppresses its transcription. 42, 43 Evidence of transcriptional activation of any miRNA by BRCA1 has not been previously reported. Our data offer a new mechanism by which BRCA1 carries out its tumor suppressor function via a previously undescribed BRCA1 → miR--146a → EGFR regulatory pathway. We have provided strong evidence that BRCA1 binds to specific regions on miR-146a BRCA1 and miR-146a regulate EGFR expression promoter through its RING and BRCT domains and thus enhances its transcription.
It is widely reported that TRAF6 and IRAK 1 are bona fide targets of miR-146a, 29 but recent studies have shown that it also targets mRNAs encoding other proteins, including EGFR. 26, 32, 33, 44, 45 We demonstrate for the first time that miR-146a directly targets the 3'UTR of EGFR in breast cancer cells. We also provide evidence that EGFR downregulation following BRCA1 overexpression is dependent on the induction of miR-146a. Several independent studies have shown that miR-146a could inhibit tumor growth and metastasis in breast and other cancers. 26, 45 Using genetically engineered mice, subsequent studies have demonstrated that miR-146a can function as a tumor suppressor gene. 46, 47 Our data showed that miR-146a levels in clinical samples strongly correlate with overall survival of TN breast cancer patients, and also with expression levels of BRCA1.
Further studies will determine if miR-146a can be used as a potential biomarker to identify the functional state of BRCA1 and EGFR in breast tumors.
Tight biological control of EGFR pathway is necessary for proper downstream signaling. EGFR overexpression results in the activation of key downstream targets that induce hyperproliferation, resistance to apoptosis and enhanced cell migration and matrix remodeling. 28 In our experiments with HCC1937 cells, we found that, in addition to total EGFR, BRCA1-deficient cells exhibited increased autophosphorylation of EGFR at Y-1068 and increase in Raf-1 and Ras. Phosphorylation of specific tyrosine residues of EGFR within the cytoplasmic domain constitutes the initial activation process. Subsequent to this, the phosphotyrosine residues serve as docking sites for intracellular signaling molecules. Phosphotyrosine Y-1068 has been shown to mediate direct interaction of EGFR to Grb2, which in turn results in RAS/MAP kinase cascade activation. 11 Although EGF signaling occurs through a variety of pathways, activation of the RAS/MAPK cascade has been associated with mammary epithelial cell growth and differentiation, as well as cancer development and progression. 48 From gene expression profiling, Hoadley et al. 49 have shown that BLBCs preferentially use the EGFR-RAS-MEK pathway.
An interaction network was built to model the potential relationship of BRCA1, miR-146a and EGFR and their associated pathways. Ingenuity Pathway Analysis (IPA) revealed their involvement in the MAPK signaling pathway (Supplementary Figure S7 ). MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, clonogenicity assay and analysis of downstream targets of EGFR further confirm the interplay of BRCA1 and miR-146a in the regulation of RAS/ MAPK signaling pathway in breast cancer cells, thereby contributing to tumor suppression.
In vitro studies on human breast luminal and basal cells have shown that basal cells express much higher levels of EGFR compared with their luminal counterparts. 49 It has also been shown that EGFR is expressed in cancer stem cells and hence could be involved in cancer stem cell renewal. 50 We investigated the contribution of miR-146a to stem cell self-renewal. Malignant cells behave similar to mammary stem and progenitor cells, proliferating in an undifferentiated state with a higher propensity for symmetric self-renewal. Our data showing an increase in the mammosphere-forming efficiency in miR-146a-deficient cells suggest enhanced symmetric self-renewal capacity of HMLE owing to an increase in EGFR.
In this study, we report a posttranscriptional mechanism of EGFR regulation by BRCA1 mediated via miR-146a. Our results suggest that the loss of miR-146a-mediated EGFR regulation is a critical step in tumor pathogenesis in BRCA1-deficient breast cancer cells. Our findings indicate that there exists an opportunity to prevent the development and progression of basal-like tumors from a state of cellular BRCA1 deficiency. 
MATERIALS AND METHODS
Chromatin immunoprecipitation
Chromatin immunoprecipitation assay was performed on HMLE and HeLa cells using the SimpleChiP Enzymatic Chromatin IP Kit (Agarose Beads) from Cell Signaling Technology (Danvers, MA, USA). The detailed protocol is given in Supplemental Experimental Procedures.
Mammosphere culture, MTS assay, clonogenicity and cell cycle analysis
The experiments were performed on HMLE, HCC1937 and HCC1937 WT BRCA1 cells. Please see Supplemental Experimental Procedures for detailed protocols.
Statistical analyses
Unless otherwise noted, data are presented as mean ± s.e.m. Student's t-test was used for assessing the significance of expression levels and comparisons, with Po 0.05 considered significant.
